BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Moderna

The first week of earnings season wraps up with major indices closely tracking the bond market in Wall Street's version of “follow the leader.” Earnings absolutely matter, but right now the Fed's policies are maybe a bigger influence.

Vaccine Stocks Climb After Moderna Added To S&P 500, With BioNTech Also Up

A new Hong Kong study has found that people fully vaccinated with the BioNTech SE (NASDAQ: BNTX) COVID-19 shot have ten times higher antibody concentrations than those who have received inactivated vaccines like China's Sinovac Biotech Ltd (NASDAQ: SVA), according to a new study published in The Lancet. Sinovac shot generated levels of the virus-targeting proteins that were “similar or lower” than the naturally occurring ones seen in recovered patients.

Lancet Study Shows BioNTech COVID-19 Vaccine Generates 10X Higher Antibody Levels Compared to Sinovac Shot

The global tally for the coronavirus-borne illness climbed above 188.9 million on Friday, while the death toll climbed further above 4.06 million, according to data aggregated by Johns Hopkins University. The U.S. leads the world with a total of 33.9 million cases and in deaths with 608,400 as the highly infectious delta variant continues to spread fast, especially in states with low vaccination rates.

Coronavirus tally: Global cases of COVID-19 near 189 million; BioNTech vaccine sees 10 times more antibodies than Sinovac one in study

Healthcare workers in Hong Kong who received the COVID-19 vaccine from BioNTech showed ten times more antibodies than those who received China's vaccine Sinovac, according to a study published in The Lancet Microbe on Thursday. "The difference in concentrations of neutralising antibodies identified in our study could translate into substantial differences in vaccine effectiveness," according to the research.

BioNTech COVID-19 vaccine antibodies ten times higher than Sinovac's: study

Pfizer

Should Investors Worry About the Pfizer-BioNTech Vaccine's Lower Efficacy Against the Delta Variant?

While antibodies are not the only measure of a vaccine's effectiveness the study likely adds to the growing pool of evidence that mRNA vaccines may offer more robust protection.

Pfizer's Covid-19 Vaccine Generated 10 Times More Antibodies Than China's Sinovac Shot, Hong Kong Study Shows

Pfizer has indicated that a third dose of its vaccine may be needed within six to 12 months after full vaccination, as initial immunity wanes and as new and more aggressive variants of the Coronavirus continue to spread. The company says that it has preliminary data to prove that an additional dose.

What's New With Pfizer's Covid-19 Vaccine?

Abbott Labs

Fulgent Genetics

Lucira Health

Roche Holding AG

Despite easing restrictions, COVID is going to be around a lot longer than many think.

5 Stocks to Own for the Surge in Coronavirus Variants

What Pfizer, BioNTech, and Moderna Are Doing to Fight the Deadly Delta Variant

They've vaccinated the largest percentage of Americans against the coronavirus.

The Best Stock for the Second Half: Moderna or BioNTech?

AstraZeneca

Johnson & Johnson

Novavax

Based on company forecasts, Wall Street estimates, and author guestimates, the top coronavirus vaccine developers will bring in billions of dollars in sales this year.

COVID-19 Vaccines: How Much Revenue Will Each Drugmaker Generate in 2021?

• Pharmaceutical company seeks FDA approval for third dose

Pfizer pushes for booster shots as WHO says greed is driving vaccine disparities

The meeting comes amid a public dispute between the drugmaker and U.S. officials on if and when Americans will need additional doses of the Covid vaccines.

Pfizer to make case to U.S. officials Monday on need for Covid vaccine booster shots

Dr. Scott Gottlieb says the United States "probably missed the window" to provide the follow-up doses before a summer wave of infections.

Declining Vaccine Efficacy—Particularly Among Older Individuals—Prompting Pfizer's Emergency Booster Request, Former FDA Chief Says

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced Thursday that they are developing a COVID-19 booster dose intended to target the delta variant. What Happened: The companies expect to shortly seek U.S. authorization for a third dose of its vaccine.

Pfizer, BioNTech Working On COVID-19 Booster Shot Targeting Delta Variant

BioNTech (BNTX) and partner Pfizer plan to get authorization for COVID-19 booster vaccine shot in the United States owing the emerging Delta variant of the virus.

BioNTech (BNTX)/ Pfizer to Seek FDA Nod for COVID-19 Booster

PFE stock is gaining these morning even as the FDA pushes back against Pfizer booster trial news and plans for a new shot. The post What to Know About the Pfizer Booster Trial and New Vaccine Moves for PFE Stock appeared first on InvestorPlace.

What to Know About the Pfizer Booster Trial and New Vaccine Moves for PFE Stock

Shares of Pfizer Inc. gained 1.9% in trading on Friday, the day after the company put out a statement saying it plans to share clinical data for its experimental COVID-19 booster shot in August. Pfizer previously told investors it would share that data and submit an application for emergency authorization in July.

Pfizer says COVID-19 booster shot data coming in August, not July

Pfizer Inc (NYSE:PFE) has asked US regulators for permission to administer a third dose of its Covid-19 vaccine in an attempt to ward new virus mutations such as the Delta variant. The news came as infections continue to surge in the UK with the latest data showing the infection rate is now one in 160 compared to one in 260 last week.

Pfizer asks for Covid-19 booster shot permission as UK infection rate jumps again

Maybe, but it's still too soon to know for sure.

Could Pfizer and Moderna Be in Trouble After the Latest COVID Vaccine Findings?

The companies are also working on an updated shot designed to take the Delta variant of the infection.

Pfizer and BioNTech Plan to Seek FDA Approval for Covid-19 Booster

Pfizer Inc. and COVID-19 vaccine partner BioNTech said late Thursday they are developing a booster shot specifically targeting the so-called Delta variant of the virus that causes the disease.

Pfizer, BioNTech to develop booster vaccine for delta variant of COVID-19

Clinical studies could begin as early as August, subject to regulatory approvals, Pfizer says.

Pfizer says it is developing a Covid booster shot to target the highly transmissible delta variant

Per the latest CDC data, the Delta variant now makes up almost half of the COVID-19 cases in the United States.

News for BioNTech SE Stock (BNTX)